# Privia Health Group, Inc.: financial statements, quarterly

PRVA · Nasdaq · CIK 1759655 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/prva.md) · [Financials](/companies/prva/financials.md) · [Filings](/companies/prva/filings.md) · [Insiders](/companies/prva/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/prva/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [417](/filings/0001759655-24-000131.md) | [441 d](/filings/0001759655-26-000010.md) | [415](/filings/0001759655-25-000050.md) | [422](/filings/0001759655-25-000093.md) | [438](/filings/0001759655-25-000110.md) | [461 d](/filings/0001759655-26-000010.md) | [480](/filings/0001759655-26-000029.md) | [521](/filings/0001759655-26-000064.md) | [580](/filings/0001759655-25-000110.md) | [541 d](/filings/0001759655-26-000010.md) | [604](/filings/0001759655-26-000029.md) | [633](/filings/0001759655-26-000064.md) |
| Operating income | $m | [5.5](/filings/0001759655-24-000131.md) | [1.4 d](/filings/0001759655-26-000010.md) | [0.8](/filings/0001759655-25-000050.md) | [5.1](/filings/0001759655-25-000093.md) | [5.8](/filings/0001759655-25-000110.md) | [5.2 d](/filings/0001759655-26-000010.md) | [5.2](/filings/0001759655-26-000029.md) | [3.3](/filings/0001759655-26-000064.md) | [14.4](/filings/0001759655-25-000110.md) | [11.3 d](/filings/0001759655-26-000010.md) | [7.4](/filings/0001759655-26-000029.md) | [11.8](/filings/0001759655-26-000064.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [2.5](/filings/0001759655-24-000131.md) | [1.9 d](/filings/0001759655-26-000010.md) | [0.8](/filings/0001759655-25-000050.md) | [3.4](/filings/0001759655-25-000093.md) | [4.0](/filings/0001759655-25-000110.md) | [2.7 d](/filings/0001759655-26-000010.md) | [2.1](/filings/0001759655-26-000029.md) | [2.5](/filings/0001759655-26-000064.md) | [6.9](/filings/0001759655-25-000110.md) | [2.8 d](/filings/0001759655-26-000010.md) | [5.6](/filings/0001759655-26-000029.md) | [7.0](/filings/0001759655-26-000064.md) |
| Net income | $m | [5.6](/filings/0001759655-24-000131.md) | [2.8 d](/filings/0001759655-26-000010.md) | [3.0](/filings/0001759655-25-000050.md) | [3.5](/filings/0001759655-25-000093.md) | [3.5](/filings/0001759655-25-000110.md) | [4.4 d](/filings/0001759655-26-000010.md) | [4.2](/filings/0001759655-26-000029.md) | [2.7](/filings/0001759655-26-000064.md) | [6.9](/filings/0001759655-25-000110.md) | [9.2 d](/filings/0001759655-26-000010.md) | [3.1](/filings/0001759655-26-000029.md) | [9.0](/filings/0001759655-26-000064.md) |
| Diluted EPS | $ per share | [0.05](/filings/0001759655-24-000131.md) | not reported | [0.02](/filings/0001759655-25-000050.md) | [0.03](/filings/0001759655-25-000093.md) | [0.03](/filings/0001759655-25-000110.md) | not reported | [0.03](/filings/0001759655-26-000029.md) | [0.02](/filings/0001759655-26-000064.md) | [0.05](/filings/0001759655-25-000110.md) | not reported | [0.02](/filings/0001759655-26-000029.md) | [0.07](/filings/0001759655-26-000064.md) |
| Basic EPS | $ per share | [0.05](/filings/0001759655-24-000131.md) | not reported | [0.03](/filings/0001759655-25-000050.md) | [0.03](/filings/0001759655-25-000093.md) | [0.03](/filings/0001759655-25-000110.md) | not reported | [0.03](/filings/0001759655-26-000029.md) | [0.02](/filings/0001759655-26-000064.md) | [0.06](/filings/0001759655-25-000110.md) | not reported | [0.02](/filings/0001759655-26-000029.md) | [0.07](/filings/0001759655-26-000064.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [330](/filings/0001759655-23-000211.md) | [390](/filings/0001759655-25-000018.md) | [351](/filings/0001759655-24-000052.md) | [387](/filings/0001759655-24-000117.md) | [422](/filings/0001759655-24-000131.md) | [491](/filings/0001759655-26-000010.md) | [469](/filings/0001759655-25-000050.md) | [390](/filings/0001759655-25-000093.md) | [441](/filings/0001759655-25-000110.md) | [480](/filings/0001759655-26-000064.md) | [420](/filings/0001759655-26-000029.md) | [412](/filings/0001759655-26-000064.md) |
| Current assets | $m | [698](/filings/0001759655-23-000211.md) | [701](/filings/0001759655-25-000018.md) | [728](/filings/0001759655-24-000052.md) | [780](/filings/0001759655-24-000117.md) | [854](/filings/0001759655-24-000131.md) | [835](/filings/0001759655-26-000010.md) | [886](/filings/0001759655-25-000050.md) | [883](/filings/0001759655-25-000093.md) | [971](/filings/0001759655-25-000110.md) | [911](/filings/0001759655-26-000064.md) | [966](/filings/0001759655-26-000029.md) | [1,025](/filings/0001759655-26-000064.md) |
| Total assets | $m | [992](/filings/0001759655-23-000211.md) | [1,000](/filings/0001759655-25-000018.md) | [1,032](/filings/0001759655-24-000052.md) | [1,078](/filings/0001759655-24-000117.md) | [1,146](/filings/0001759655-24-000131.md) | [1,136](/filings/0001759655-26-000010.md) | [1,184](/filings/0001759655-25-000050.md) | [1,273](/filings/0001759655-25-000093.md) | [1,351](/filings/0001759655-25-000110.md) | [1,369](/filings/0001759655-26-000064.md) | [1,418](/filings/0001759655-26-000029.md) | [1,489](/filings/0001759655-26-000064.md) |
| Current liabilities | $m | [394](/filings/0001759655-23-000211.md) | [387](/filings/0001759655-25-000018.md) | [404](/filings/0001759655-24-000052.md) | [430](/filings/0001759655-24-000117.md) | [479](/filings/0001759655-24-000131.md) | [449](/filings/0001759655-26-000010.md) | [471](/filings/0001759655-25-000050.md) | [535](/filings/0001759655-25-000093.md) | [583](/filings/0001759655-25-000110.md) | [569](/filings/0001759655-26-000064.md) | [601](/filings/0001759655-26-000029.md) | [634](/filings/0001759655-26-000064.md) |
| Total liabilities | $m | [401](/filings/0001759655-23-000211.md) | [393](/filings/0001759655-25-000018.md) | [409](/filings/0001759655-24-000052.md) | [434](/filings/0001759655-24-000117.md) | [483](/filings/0001759655-24-000131.md) | [452](/filings/0001759655-26-000010.md) | [474](/filings/0001759655-25-000050.md) | [539](/filings/0001759655-25-000093.md) | [588](/filings/0001759655-25-000110.md) | [578](/filings/0001759655-26-000064.md) | [612](/filings/0001759655-26-000029.md) | [651](/filings/0001759655-26-000064.md) |
| Shareholders' equity | $m | [545](/filings/0001759655-23-000211.md) | [561](/filings/0001759655-25-000018.md) | [577](/filings/0001759655-24-000052.md) | [595](/filings/0001759655-24-000117.md) | [615](/filings/0001759655-24-000131.md) | [635](/filings/0001759655-26-000010.md) | [659](/filings/0001759655-25-000050.md) | [683](/filings/0001759655-25-000093.md) | [709](/filings/0001759655-25-000110.md) | [737](/filings/0001759655-26-000064.md) | [753](/filings/0001759655-26-000029.md) | [782](/filings/0001759655-26-000064.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [22.5 d](/filings/0001759655-24-000131.md) | [64.1 d](/filings/0001759655-26-000010.md) | [(33.1)](/filings/0001759655-25-000050.md) | [34.5 d](/filings/0001759655-25-000093.md) | [33.2 d](/filings/0001759655-25-000110.md) | [74.8 d](/filings/0001759655-26-000010.md) | [(24.1)](/filings/0001759655-26-000029.md) | [8.0 d](/filings/0001759655-26-000064.md) | [52.0 d](/filings/0001759655-25-000110.md) | [128 d](/filings/0001759655-26-000010.md) | [(49.5)](/filings/0001759655-26-000029.md) | [1.1 d](/filings/0001759655-26-000064.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001759655-23-000211.md) | [0.0 d](/filings/0001759655-24-000022.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [125](/filings/0001759655-23-000211.md) | [124](/filings/0001759655-24-000052.md) | [125](/filings/0001759655-24-000117.md) | [125](/filings/0001759655-24-000131.md) | [125](/filings/0001759655-25-000050.md) | [125](/filings/0001759655-25-000093.md) | [126](/filings/0001759655-25-000110.md) | [128](/filings/0001759655-26-000029.md) | [128](/filings/0001759655-26-000064.md) | [129](/filings/0001759655-25-000110.md) | [131](/filings/0001759655-26-000029.md) | [132](/filings/0001759655-26-000064.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 127,734,207 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001759655-26-000064.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.